Clik here to view.
Life Sciences Company Alcobra Plans To Raise $15-20M On IPO
Israeli company Alcobra Ltd., which develops treatments for Attention Deficit Hyperactive Disorder (ADHD), has filed a draft prospectus with the American SEC. The Israeli company plans to hold an IPO...
View ArticleClik here to view.
Pharmaceutical Company Alcobra Raises $25M On IPO
Israeli company Alcobra Pharmaceuticals, which is developing medication to treat Attention Deficit Hyperactive Disorder (ADHD), has raised $25 million in a Nasdaq IPO. The company is valued at $113...
View ArticleClik here to view.
ADHD Treatment Company Alcobra Raises $33M
October 27, 2013 | Israeli company Alcobra Pharmaceuticals, which develops Attention Deficit Hyperactive Disorder (ADHD) treatments, has raised $33 million on a secondary Nasdaq offering. The company...
View ArticleClik here to view.
Alcobra Files For $100M NASDAQ Offering
July 17, 2014 | Alcobra Pharmaceuticals filed a prospectus for a $100 million offering on NASDAQ. The company has developed alternative drugs for the treatment of ADHD based on its research. In May...
View ArticleClik here to view.
Biomed Company Alcobra Raises $40M In Nasdaq Offering
November 16, 2015 | Israeli ADHD drug development company Alcobra has raised $40 million in its offering on the Nasdaq. The company announced on Friday that it has priced its public offering of...
View Article
